Provided is a novel bacteriophage CJ23 (KCCM11365P). In addition, the present invention relates to an antibacterial composition including the bacteriophage CJ23 (KCCM11365P) as an active ingredient. Further, provided is a method of preventing and/or treating infectious diseases by avian pathogenic Escherichia coli(APEC) in birds using the bacteriophage CJ23(KCCM11365P) or the antibacterial composition containing the bacteriophage CJ23(KCCM11365P) as an active ingredient.

The present invention relates to a bacteriophage composition comprising one or more (suitably two or more, or three) bacteriophages selected from Sa87, J-Sa36, Sa83, J-Sa37, or mutants thereof, use of the same for medical or non-medical applications, kits, bandage, and wound dressing comprising the same.

Modified probiotics, pharmaceutical compositions thereof, and methods of modulating and treating disorders are disclosed.

Disclosed herein are methods and systems for rapid detection of microorganisms in a sample. A genetically modified bacteriophage is also disclosed which comprises an indicator gene in the late gene region. The specificity of the bacteriophage, such as Salmonella-specific bacteriophage, allows detection of a specific microorganism, such as Salmonella spp. and an indicator signal may be amplified to optimize assay sensitivity.

Disclosed herein are novel synthetic bacteriophages and bacteriophage compositions, methods of production thereof, and therapeutic uses thereof.

The present invention related to a method for producing or propagating an engineered bacteriophage, comprising the steps of: providing a functional synthetic genome of an engineered bacteriophage being able to infect a target bacterium; providing a recipient bacterium; transforming the recipient bacterium with the functional synthetic genome in a transformation step, yielding a transformed recipient bacterium; incubating the transformed recipient bacterium in a first incubation step, wherein the engineered bacteriophage is propagated within the transformed recipient bacterium; and further incubating the transformed recipient bacterium or the propagated engineered bacteriophage released from the transformed recipient bacterium with the target bacterium in a second incubation step, wherein the propagated engineered bacteriophage infects the target bacterium and is further propagated within the target bacterium, and wherein the recipient bacterium is a cell wall-deficient bacterium.

Modified probiotics, pharmaceutical compositions thereof, and methods of modulating and treating disorders are disclosed.

The present disclosure as disclosed in various embodiments relates to methods and compositions of treating obesity, inflammation, or obesity-associated metabolic disorders with bacteriophages and processes for preparing the compositions.

Some aspects of the present disclosure provide methods for evolving recombinases to recognize target sequences that differ from the canonical recognition sequences. Some aspects of this disclosure provide evolved recombinases, e.g., recombinases that bind and recombine naturally-occurring target sequences, such as, e.g., target sequences within the human Rosa26 locus. Methods for using such recombinases for genetically engineering nucleic acid molecules in vitro and in vivo are also provided. Some aspects of this disclosure also provide libraries and screening methods for assessing the target site preferences of recombinases, as well as methods for selecting recombinases that bind and recombine a non-canonical target sequence with high specificity.

A composition or matrix comprising a bacteriophage and nanofibrillar cellulose or a derivative thereof in a wet or dry state is disclosed.